No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes.
Saved in:
| Title: | No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes. |
|---|---|
| Authors: | Lennox, Ashley L.1 (AUTHOR) alennox@geron.com, Huang, Fei1 (AUTHOR), González‐Sales, Mario2,3 (AUTHOR), Wan, Ying1 (AUTHOR), Sun, Libo1 (AUTHOR), Berry, Tymara1 (AUTHOR), Feller, Faye1 (AUTHOR), Morcos, Peter N.4 (AUTHOR) |
| Source: | CTS: Clinical & Translational Science. Dec2025, Vol. 18 Issue 12, p1-8. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17528054 |
|---|---|
| DOI: | 10.1111/cts.70431 |
